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Dear Editor: 
We read the paper “Hepatocellular carcinoma tumour burden score to stratify prognosis 
after resection” with interest published in a recent issue of British Journal of Surgery1. In this 
elegant, multi-center study including 1,053 patients with hepatocellular carcinoma (HCC) 
undergoing surgical resection, authors demonstrate that tumour burden score (TBS) is 
correlated with cancer stage as a marker of tumor burden. Although their findings are 
interesting, some concerns may deserve further discussion. 
We have alternatively proposed another useful marker, total tumour volume (TTV), to 
represent tumour burden specifically for HCC by using the following mathematical equation: 
    Tumour volume (cm3) = 4/3 x 3.14 x (maximum radius of the tumour nodule in cm)3 
TTV is the sum of the tumour volumes of every nodule: 
    TTV (cm3) = Tumour volume of (tumour nodule 1 + tumour nodule 2 + …… + tumour 
nodule N) 
Our data showed that TTV, as a continuous variable, is a feasible prognostic marker for 
patients with HCC undergoing locoregional therapy2,3. In addition, its association with 
ɑ-fetoprotein can be used to predict post-operative tumour recurrence of HCC4. Moreover, 
TTV-based cancer staging system was shown to have a better prognostic accuracy for HCC 
from early to late stages5. The reason for its excellent predictive power is because TTV is 
highly linked with aggressive tumour behavior including vascular invasion, metastasis, liver 
dysfunction and performance status. All these features make TTV an authentic candidate to 
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represent tumour burden for HCC. 
Therefore, although TBS may appear as a surrogate marker for surgical HCC, a more 
in-depth evaluation of TBS for HCC patients undergoing different treatments and a direct 
comparison with TTV are urgently required to consolidate their application in clinical practice. 
Further studies from international cohorts are needed to address this issue. 
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